KMT2C and cancer: Recent work from our group identified compensatory MLL1 activity as a driver of metabolic rewiring in the absence of MLL3/4 function, suggesting that MLL1/COMPASS may also be a targetable molecular dependency in cancers with mutations affecting MLL3, MLL4, or their shared COMPASS partner, the H3K27 demethylase KDM6A (70).